scholarly journals Heart Transplantation as a Treatment Method for Refractory Heart Failure due to Post-myocarditis Dilated Cardiomyopathy: a Clinical Case

2019 ◽  
Vol 18 (2) ◽  
pp. 125-133
Author(s):  
Larisa A. Balykova ◽  
Elena I. Naumenko ◽  
Nataljya V. Ivyanskaya ◽  
Yulia A. Petrushkina ◽  
Ekaterina A. Vlasova ◽  
...  
Keyword(s):  
Heart Failure ◽  
Heart Transplantation ◽  
Dilated Cardiomyopathy ◽  
Clinical Case ◽  
Treatment Method ◽  
Circulatory Support ◽  
Chronic Cardiac Failure ◽  
Refractory Heart Failure ◽  
Life Threatening ◽  
Proper Analysis

Background. Implementation of mechanical circulatory support and heart transplantation technologies in paediatric clinical practice is changing approaches of diagnostics and treatment of heart failure (HF) in children. The experience of carrying out such operations in Russian Federation is extremely limited until recently due to absence of legal mechanisms of people declaration of intention recording about postmortal use of organs for transplantation.Clinical Case Description. The rare clinical case of drug-refractory (cardiotonic agents and cardioverter defibrillator implantation) chronic cardiac failure caused by post-myocarditis dilated cardiomyopathy (DCM) which demanded heart transplantation. Postoperative course, specific and non-specific complications, diagnostics and correction approaches are described.Conclusion. In the absence of proper analysis of non-specific slight symptoms myocarditis can progress to DCM and be complicated by development of refractory HF. The only method of sustaining child’s life in such case is heart transplantation which is connected with high risk of numerous and life-threatening complications.

scholarly journals Management of a patient with terminal chronic heart failure.

2018 ◽  
Vol 96 (3) ◽  
pp. 273-276
Author(s):  
N. A. Kosheleva ◽  
Elena Yu. Ponomareva ◽  
D. S. Sedov
Keyword(s):  
Heart Failure ◽  
Drug Therapy ◽  
Chronic Heart Failure ◽  
Heart Transplantation ◽  
Dilated Cardiomyopathy ◽  
Patient Management ◽  
Clinical Case ◽  
Clinical Manifestations

The presented clinical case describes the development of diffuse myocarditis in a 31-year-old man with the outcome of dilated cardiomyopathy and terminal chronic heart failure, resistant to drug therapy that required heart transplantation. Discussed aspects of diagnosis, clinical manifestations, tactics of patient management and indications for heart transplantation.

scholarly journals Pediatric Palliative Care in the Heart Failure, Ventricular Assist Device and Transplant Populations: Supporting Patients, Families and Their Clinical Teams

Children ◽  
2021 ◽  
Vol 8 (6) ◽  
pp. 468
Author(s):  
Kyle D. Hope ◽  
Priya N. Bhat ◽  
William J. Dreyer ◽  
Barbara A. Elias ◽  
Jaime L. Jump ◽  
...  
Keyword(s):  
Heart Failure ◽  
Palliative Care ◽  
Heart Transplantation ◽  
Ventricular Assist Device ◽  
Mechanical Circulatory Support ◽  
Pediatric Palliative Care ◽  
Circulatory Support ◽  
Assist Device ◽  
Ventricular Assist ◽  
Patients With Heart Failure

Heart failure is a life-changing diagnosis for a child and their family. Pediatric patients with heart failure experience significant morbidity and frequent hospitalizations, and many require advanced therapies such as mechanical circulatory support and/or heart transplantation. Pediatric palliative care is an integral resource for the care of patients with heart failure along its continuum. This includes support during the grief of a new diagnosis in a child critically ill with decompensated heart failure, discussion of goals of care and the complexities of mechanical circulatory support, the pensive wait for heart transplantation, and symptom management and psychosocial support throughout the journey. In this article, we discuss the scope of pediatric palliative care in the realm of pediatric heart failure, ventricular assist device (VAD) support, and heart transplantation. We review the limited, albeit growing, literature in this field, with an added focus on difficult conversation and decision support surrounding re-transplantation, HF in young adults with congenital heart disease, the possibility of destination therapy VAD, and the grimmest decision of VAD de-activation.

Heart transplantation and mitral valve repair in pediatric patients with refractory heart failure

2003 ◽  
Vol 35 (1) ◽  
pp. 463-465 ◽  
Author(s):  
S.-S Wang ◽  
R.-B Hsu ◽  
Y.-S Chen ◽  
W.-J Ko ◽  
N.-K Chou ◽  
...  
Keyword(s):  
Heart Failure ◽  
Mitral Valve ◽  
Heart Transplantation ◽  
Mitral Valve Repair ◽  
Pediatric Patients ◽  
Valve Repair ◽  
Refractory Heart Failure

scholarly journals Heart Transplantation and the Batista Operation for Children With Refractory Heart Failure

2001 ◽  
Vol 65 (4) ◽  
pp. 289-293 ◽  
Author(s):  
Shuenn-Nan Chiu ◽  
Mei-Hwan Wu ◽  
Jou-Kou Wang ◽  
Jiuan-Huey Lin ◽  
Yih-Shyang Chen ◽  
...  
Keyword(s):  
Heart Failure ◽  
Heart Transplantation ◽  
Refractory Heart Failure

Surgical methods of treatment of chronic heart failure and their place in modern clinical recommendations

2020 ◽  
Vol 22 (4) ◽  
pp. 183-191
Author(s):  
O. T. Kotsoeva ◽  
A. V. Koltsov ◽  
V. V. Tyrenko ◽  
A. A. Ialovets
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Chronic Heart Failure ◽  
Left Ventricle ◽  
Heart Transplantation ◽  
Mechanical Circulatory Support ◽  
Circulatory Support ◽  
Surgical Methods ◽  
The Moment

This review discusses a number of aspects of surgical methods for treating severe chronic heart failure: resynchronizing therapy, mechanical circulatory support systems, and heart transplantation. Surgical methods for the treatment of heart failure are a rapidly developing field of modern cardiology and cardiac surgery. The main surgical method of treatment was and remains orthotopic transplantation of a donor heart. The advent of implantable systems has affected the problem of heart transplantation. Over the past decade, the use of mechanical circulatory support systems has grown significantly. At the moment, there are 3 main directions: creating devices for auxiliary blood circulation, various modes and methods of electrical stimulation of the myocardium, creating devices that mechanically remodel the heart chambers (left ventricle). All of these directions to some extent (depending on the evidence base) have found their place in modern recommendations for the treatment of chronic heart failure. The use of mechanical left ventricular remodeling shows good results in patients suffering from symptomatic heart failure, which leads to a significant and persistent decrease in the volume of the left ventricle and improvement of its function, symptoms and quality of life. Despite the fact that at the moment the geography and prevalence of their use is small, the number of implanted devices will only grow. Thus, given the need for frequent hospitalizations and high treatment costs, it is necessary to improve modern methods of surgical treatment of severe and terminal heart failure, make them more accessible, which will affect the duration and quality of life of these patients.

scholarly journals Ventricular resynchronization through biventricular cardiac pacing for the treatment of refractory heart failure in dilated cardiomyopathy

2002 ◽  
Vol 78 (1) ◽  
pp. 45-50 ◽  
Author(s):  
Silas S. Galvão Fº ◽  
Cecília M. B. Barcellos ◽  
J. Tarcísio M. Vasconcelos ◽  
Jaime G. M. Arnez ◽  
Kátia N. Couceiro ◽  
...  
Keyword(s):  
Heart Failure ◽  
Dilated Cardiomyopathy ◽  
Cardiac Pacing ◽  
Refractory Heart Failure

scholarly journals Value of SERCA2a as a Biomarker for the Identification of Patients with Heart Failure Requiring Circulatory Support

2021 ◽  
Vol 11 (11) ◽  
pp. 1122
Author(s):  
Meryem Ezzitouny ◽  
Esther Roselló-Lletí ◽  
Manuel Portolés ◽  
Ignacio Sánchez-Lázaro ◽  
Miguel Ángel Arnau-Vives ◽  
...  
Keyword(s):  
Heart Failure ◽  
Sarcoplasmic Reticulum ◽  
Heart Transplantation ◽  
Predictive Value ◽  
Mechanical Circulatory Support ◽  
Circulatory Support ◽  
Bridge To Recovery ◽  
Blood Samples ◽  
Cytoplasmic Transport ◽  
Patients With Heart Failure

Background: Heart failure (HF) alters the nucleo-cytoplasmic transport of cardiomyocytes and reduces SERCA2a levels, essential for intracellular calcium homeostasis. We consider in this study whether the molecules involved in these processes can differentiate those patients with advanced HF and the need for mechanical circulatory support (MCS) as a bridge to recovery or urgent heart transplantation from those who are clinically stable and who are transplanted in an elective code. Material and method: Blood samples from 29 patients with advanced HF were analysed by ELISA, and the plasma levels of Importin5, Nucleoporin153 kDa, RanGTPase-Activating Protein 1 and sarcoplasmic reticulum Ca2+ ATPase were compared between patients requiring MCS and those patients without a MCS need prior to heart transplantation. Results: SERCA2a showed significantly lower levels in patients who had MCS compared to those who did not require it (0.501 ± 0.530 ng/mL vs. 1.123 ± 0.661 ng/mL; p = 0.01). A SERCA2a cut-off point of 0.84 ng/mL (AUC 0.812 ± 0.085, 95% CI: 0.646–0.979; p = 0.004) provided a 92% sensitivity, 62% specificity, 91% negative predictive value and 67% positive predictive value. Conclusions: In this cohort, patients with advanced HF and a need for MCS have shown significantly lower levels of SERCA2a as compared to stable patients without a need for MCS prior to heart transplantation. This is a small study with preliminary findings, and larger-powered dedicated studies are required to confirm and validate these results.

Adult Cardiac Transplantation

1996 ◽  
Vol 11 (2) ◽  
pp. 79-89
Author(s):  
G. Daniel Martich ◽  
Arthur J. Boujoukos
Keyword(s):  
Heart Failure ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Heart Transplantation ◽  
Immunosuppressive Agents ◽  
Refractory Heart Failure ◽  
Operative Care ◽  
Immunosuppressed Patients ◽  
Artery Disease ◽  
Poor Functional Status

Patients with severe drug-refractory heart failure experience one of two modes of death. Either they collapse from an arrhythmia and are deemed to have had sudden death, or they die of progressive congestive heart failure. In either instance, their poor functional status during life limits their ability to perform usual daily activities. Currently, the only proven long-term benefit to these patients is heart transplantation. The technique that led to the first human-to-human heart transplantation nearly 30 years ago has changed very little; however, refinements in post operative care have kept research in this field at the fore for many years. Immediate postoperative hemodynamic stabilization by experienced clinicians may improve a patient's chances of survival after heart transplantation. Improved immunosuppressive agents have decreased life-threatening rejection episodes. Better knowledge of the infectious diseases that attack these immunosuppressed patients has also contributed to the nearly 85% one-year survival of heart transplantation recipients. The longest surviving heart transplantation recipient remains alive and well after more than 22 years. The development of transplant-related coronary artery disease may be the only transplantation-associated factor that keeps recipients from living for many decades. Transplantation coronary artery disease leads the list of late causes of mortality. Unlike native coronary artery disease, there exists ongoing difficulty in both diagnosis and treatment of this dreaded complication. We cover current standards and future possibilities in adult heart transplantation. We look at history, demographics, indications, management, and outcome in these patients, as well as future goals.

Sign in / Sign up

Export Citation Format

Share Document